269 completed, 83 terminated, 43 unknown, 31 recruiting. 283 Phase 2, 219 Phase 1, 36 Phase 3, 13 Not applicable, 7 Early Phase 1.
Follow aldesleukin: new trials by email Literature Review of aldesleukin trials Research Report on aldesleukin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors Aldesleukin, Biospecimen Collection, Chest Radiography - Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor | Phase 2 | Not yet recruiting | Joal Beane | 59 | 2027-02-15 | 2026-10-13 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-10-27 | 2026-10-22 |
| A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII - Ovarian Cancer, Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of Chicago | 24 | 2026-09-09 | 2026-10-13 |
| Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo - Alzheimer Dementia (AD) | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 30 | 2026-09-01 | 2026-09-23 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma AZD4045, Daratumumab, Aldesleukin - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 101 | 2026-07-27 | 2026-10-15 |
| A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma Tumour Infiltrating Lymphocytes Adoptive Cell Therapy, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Aldesleukin - Melanoma (Skin Cancer), Melanoma Metastatic | Phase 2 | Not yet recruiting | East Metropolitan Health Service, Australia | 10 | 2026-07-01 | 2026-06-16 |
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
| Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | David Bartlett, MD | 10 | 2026-06-03 | 2026-08-04 |
| Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2) - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 10 | 2026-05-01 | 2026-04-07 |
| Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells Interleukin-2 (Aldesleukin), Standard care - Coronary Artery Disease, Myocardial Infarction (MI) | Not applicable | Recruiting | Cambridge University Hospitals NHS Foundation Trust | 24 | 2026-03-31 | 2026-05-28 |
| TIL Therapy in cSCC and MCC LN-145, Cyclophosphamide, Fludarabine - Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Karam Khaddour, MD, MS | 14 | 2026-02-10 | 2026-02-13 |
| Efficacy of Interleukin-2 in Triple Negative Breast Cancer Human Interleukin-2 (IL-2) (Proleukin) - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Nova Scotia Health Authority | 10 | 2026-01-02 | 2025-02-12 |
| STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma Aldesleukin, Biopsy, Biospecimen Collection - Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-12-05 | 2025-12-24 | |
| A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine - Gastrointestinal Carcinoma, Pancreatic Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-09-09 | 2025-09-11 | |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-06 |
| Adding IL-2 to Tebentafusp to Eradicate Cancer Progression Aldesleukin - Uveal Melanoma, Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | St Vincent's Hospital, Sydney | 8 | 2025-06-01 | 2025-07-14 |
| To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate - Melanoma Stage III, Melanoma Stage IV | Phase 1 | Recruiting | Inge Marie Svane | 10 | 2025-04-01 | 2025-08-24 |
| A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer Aldesleukin, Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes, Biopsy - Triple Negative Breast Cancer | Phase 1 | Recruiting | University of Southern California | 20 | 2024-12-17 | 2026-05-19 |
| Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma LN-144, Cyclophosphamide, Mesna - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 | Withdrawn | James Isaacs, MD | 2024-12-02 | 2025-06-05 | |
| Diabetes Islet Preservation Immune Treatment Anti-Thymocyte Globulin (ATG), Interleukin 2, Exenatide - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Withdrawn | Camillo Ricordi and Jay Skyler | 2024-06-01 | 2026-01-15 |
Showing 20 of 471. Sign in to see all of them.
Melanoma (138) · Carcinoma, Renal Cell (52) · Kidney Neoplasms (43) · Leukemia, Myeloid, Acute (38) · Neoplasm Metastasis (37) · HIV Infections (33) · Leukemia (33) · Lymphoma (30) · Breast Neoplasms (26) · Ovarian Neoplasms (24) · Carcinoma, Non-Small-Cell Lung (22) · Lymphoma, Non-Hodgkin (22) · Skin Neoplasms (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (19) · Lymphoma, Follicular (18)
National Cancer Institute (NCI) (104) · National Institute of Allergy and Infectious Diseases (NIAID) (29) · Fred Hutchinson Cancer Center (26) · M.D. Anderson Cancer Center (24) · H. Lee Moffitt Cancer Center and Research Institute (12) · Masonic Cancer Center, University of Minnesota (10) · Inge Marie Svane (8) · Jonsson Comprehensive Cancer Center (7) · National Institutes of Health Clinical Center (CC) (7) · Peking University People's Hospital (7) · Barbara Ann Karmanos Cancer Institute (6) · Cambridge University Hospitals NHS Foundation Trust (6) · Roswell Park Cancer Institute (6) · St. Jude Children's Research Hospital (6) · Chiron Corporation (5)
United States (370) · United Kingdom (21) · Denmark (14) · France (13) · Australia (12) · Canada (12) · China (10) · Germany (9) · Italy (9) · Netherlands (8) · Austria (7) · Israel (7) · Belgium (6) · Spain (6) · Sweden (6)
Steven A Rosenberg, M.D. (24) · Steven A. Rosenberg, MD, PhD (20) · James C Yang, M.D. (7) · Steven Rosenberg, M.D. (6) · Zhanguo Li (5) · Amod Sarnaik, M.D. (4) · Aude Chapuis (4) · Richard L. White, MD (4) · Robert O. Dillman, MD, FACP (4) · Cassian Yee (3) · Cassian Yee, MD (3) · Christian S Hinrichs, MD (3) · John A. Thompson, MD (3) · John P. Hanson, MD (3) · Marcus Butler, M.D. (3)
PMID 22555974, PMID 35537408, PMID 23861247, PMID 30714987, PMID 19828532, PMID 24870935, PMID 25432172, PMID 30573690, PMID 32747469, PMID 33986124, PMID 38816232, PMID 10890744, PMID 11331327, PMID 11359672, PMID 11585760, PMID 12750167, PMID 12810695, PMID 14581425, PMID 15112270, PMID 15206062, PMID 15337804, PMID 15514371, PMID 15534491, PMID 16006888, PMID 16170182, PMID 16237114, PMID 16260693, PMID 16275934, PMID 16283570, PMID 16640817, PMID 16670265, PMID 16706633, PMID 16760795, PMID 16817692, PMID 16982775, PMID 17023156, PMID 17339422, PMID 17443000, PMID 17563739, PMID 17889355, PMID 17932908, PMID 18157014, PMID 18162124, PMID 18256325, PMID 18299450, PMID 18431498, PMID 18509084, PMID 18628467, PMID 18794104, PMID 19001327
P30CA022453 (7), P30CA015704 (6), P01CA018029 (4), P30CA033572 (4), K12CA076930 (3), P30CA016056 (3), U10CA031946 (3), U10CA098543 (3), 2014 (2), 2019 (2), N01CM17102 (2), P01CA015396 (2), P30CA006973 (2), P30CA015083 (2), P30CA016672 (2)